基本信息:
- 专利标题： MODIFIED CELL AND USE THEREOF IN GENE AND CELL THERAPY
- 申请号：US17490582 申请日：2021-09-30
- 公开(公告)号：US20220105134A1 公开(公告)日：2022-04-07
- 发明人： Zhiyuan Cao , Lei Xiao , Yuzhe Peng , Wei Ding , Wensheng Wang
- 申请人： Innovative Cellular Therapeutics Holdings, Ltd. , Innovative Cellular Therapeutics, Inc.
- 申请人地址： KY Grand Cayman; US MD Rockville
- 专利权人： Innovative Cellular Therapeutics Holdings, Ltd.,Innovative Cellular Therapeutics, Inc.
- 当前专利权人： Innovative Cellular Therapeutics Holdings, Ltd.,Innovative Cellular Therapeutics, Inc.
- 当前专利权人地址： KY Grand Cayman; US MD Rockville
- 主分类号： A61K35/17
- IPC分类号： A61K35/17 ; C07K14/47 ; C07K14/725
摘要：
The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.
公开/授权文献:
- US11944645B2 Modified cell and use thereof in gene and cell therapy 公开/授权日：2024-04-02
IPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K35/00 | 含有其有不明结构的原材料或其反应产物的医用配制品 |
| --------A61K35/02 | .来源于非生命物质的 |
| ----------A61K35/14 | ..血液 |
| ------------A61K35/17 | ...淋巴细胞；B细胞；T细胞；自然杀伤细胞；干扰素激活或细胞因子激活的淋巴细胞 |